Prognostic Significance of p53, bcl-2 and EGFR in Carcinoma of the Endometrium

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Acta Cytologica

• Publication date

  1999-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000331351PMID 10578976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Principles and Practice of Surgical Pathology and Cytopathology

  1999cited by this paper
• Expression of cathepsin-D, CA125 and epidermal growth factor receptor in imprint smears of ovarian carcinoma.

  1997cited by this paper
• P53 protein expression and DNA ploidy in common epithelial tumors of the ovary.

  1997cited by this paper
• Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity.

  1996cited by this paper
• The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study

  1995cited by this paper
• p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.

  1995cited by this paper
• Prognostic value of bcl-2 expression in invasive breast cancer.

  1995cited by this paper
• Apoptosis suppressing protein bcl‐2 is expressed in well‐differentiated breast carcinomas with favourable prognosis

  1995cited by this paper
• Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma.

  1995cited by this paper
• Risk factors and p53 nuclear overexpression in early stage intestinal-type adenocarcinoma of the stomach.

  1995cited by this paper
• Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance.

  1995cited by this paper
• Clinical implications of the p53 tumor-suppressor gene.

  1994cited by this paper
• Prognostic indicators for early-stage breast-carcinoma .2. Value of cathepsin-d expression, detected by immunocytochemistry - a multiparametric study.

  1994cited by this paper
• Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.

  1994cited by this paper
• Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.

  1994cited by this paper
• Endometrial cancer: prognostic factors.

  1994cited by this paper
• Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer

  1994cited by this paper
• Prognostic significance of cathepsin-D in patients with breast cancer.

  1993cited by this paper
• International federation of gynecology and obstetrics staging of endometrial cancer 1988

  1993cited by this paper
• Clinical implications of the p53 tumor-suppressor gene.

  1993cited by this paper
• Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

  1993cited by this paper
• CA 125 and CA 19‐9 immunolocalization in normal, hyperplastic, and carcinomatous endometrium

  1993cited by this paper
• The Uterine Corpus

  1992cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix

  1990cited by this paper
• Immunocytochemical assay of estrogen receptors in endometrial carcinoma with monoclonal antibodies. Comparison with biochemical assay

  1986cited by this paper
• Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma.

  1985cited by this paper
• Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

  1980cited by this paper

• Histopathological and Immunohistochemical Prognostic Factors in High-Grade Non-Endometrioid Carcinomas of the Endometrium (HG-NECs): Is It Possible to Identify Subgroups at Increased Risk?

  2023cites this paper
• HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL PROGNOSTIC FACTORS IN HIGH-GRADE NON-ENDOMETRIOID CARCINOMAS OF THE ENDOMETRIUM (HG-NECs). IS IT POSSIBLE TO IDENTIFY SUB-GROUPS AT INCREASED RISK?

  2021cites this paper
• Biologia molecular no carcinoma de endométrio: uma revisão

  2015cites this paper
• Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis

  2015cites this paper
• The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies

  2014influential citation
• A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

  2013cites this paper
• Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?

  2010cites this paper
• Evaluation of apoptosis in cytologic specimens

  2010cites this paper
• Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

  2008cites this paper
• The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas

  2006cites this paper
• Association between Bcl-2 expression and tumor recurrence in cervical cancer: a matched case-control study.

  2006cites this paper
• The association between p53 expression, stage and histological features in endometrial cancer.

  2005cites this paper
• Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines.

  2004cites this paper
• The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma

  2004cites this paper
• [Endometrioid adenocarcinoma arising from adenomyosis. A case report and literature review].

  2004cites this paper
• Chapter 21 – Treatment of Recurrent Endometrial Cancer: Chemotherapy, Hormonal Therapy, and Radiotherapy

  2004cites this paper
• The use of P53, PTEN, and C‐erbB‐2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma

  2004cites this paper
• p53 overexpression as a prognostic indicator in endometrial carcinoma.

  2003cites this paper
• Apoptosis and apoptosis‐related factors Bcl‐2, Bax, tumor necrosis factor‐α, and NF‐κB in human endometrial hyperplasia and carcinoma

  2002cites this paper
• Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma.

  2002cites this paper
• Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology

  2002cites this paper
• Traitement conservateur de l'hyperplasie atypique et du cancer de l'endomètre au stade précoce : Gynécologie oncologique

  2001cites this paper
• Analyse der (anti-)östrogenen Wirkmechanismen von Raloxifen und Tamoxifen in Endometrium- und Mammakarzinomen

  2001cites this paper
• ENDOMETRİUM KANSERİNDE PROGNOSTİK FAKTÖRLER

  2001cites this paper
• Endometrioid adenocarcinoma arising from adenomyosis: Report and immunohistochemical analysis of an unusual case

  2001cites this paper
• Prognosis for papillary serous carcinoma of the endometrium after surgical staging

  2001cites this paper